A Study of SSS17 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This is a first-in-human, Phase 1, single-center, randomized, single-blind, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53 receiving active drug and 12 receiving placebo) will participate in this study.

Detailed Description
-----------------
The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures. The improved Fibonacci dose escalation design will be implemented. The protocol specifies 10 mg, oral, one time for the first cohort without placebo control. Successive cohorts will be given doses up to 540 mg with placebo parallel control. Only no observation meets the criteria under stop rules, dose will escalate to the next higher level. The study will be divided into 2 stages: 1st period (fast) and 2nd period(fed). First period (fast): Subjects will be allocated 1:4 to receive placebo or SSS17, which will be administered by oral route. At each dose, tolerability, safety, PK and PD characteristics will be investigated. Second period (fed): in order to investigate the effects of food on PK and PD of SSS17. Subjects in one cohort will be administered again after meal on Day15. The accurate dose will be adjusted according to the findings in 1st period (fast)

Official Title
-----------------
A Single Dose Escalation Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of SSS17 in Chinese Healthy Subject

Conditions
-----------------
Anemia in Chronic Kidney Diseases

Intervention / Treatment
-----------------
* Drug: SSS17
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body weight≥50 for male or ≥45 for female, and BMI between 19.0-26.0 kg/m2 Good general health as determined by the investigator based on medical history, physical examination, vital signs, 12-lead ECG, clinical laboratory tests and B-type ultrasound test. Participants of reproductive potential must agree to utilize reliable methods of contraception from screening to 6 months after the last administration of the study intervention. No plan for sperm (or egg) donation or pregnancy. Understand and sign the informed consent. Ability to understand and follow study-related instruction Exclusion Criteria: A known allergy to any component of the SSS17 formulation, or allergy history of two kinds of drugs or food Medical history or conditions of digestive system. Female volunteers who are pregnant, menstrual, lactating or menopause with hormone therapy. Eyes diseases, including diabetic retinopathy, age-related macular degeneration. Vascular anomalies. Drug, alcohol or nicotine addiction. Blood donation or bleeding (more than 200 ml). Experience of treatment with EPO or blood transfusion. Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance Abnormal results in test of TIBC, serum iron or ferritin Acute diseases before administration. Other situations that the researcher believes may affect validity judgment or are not suitable for participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose Escalation SSS17<br>Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15) | Drug: SSS17<br>* SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.<br>|
| Placebo Comparator: Escalation matching Placebo<br>Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15) | Drug: Placebo<br>* matched placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AEs | assessment AEs by frequency, severity | up to Day14 or 29 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum plasma concentration (Cmax) of SSS17 | Plasma samples will be collected and Cmax will be assessed. | [ up to 48 hours post-dose] | 
| Area under the concentration-time curve (AUC) of plasma concentration of SSS17 | Plasma samples will be collected and the AUC from zero to infinity will be assessed. | [ up to 48 hours post-dose] | 
| Time-to-Cmax (Tmax) of SSS 17 | Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve. | [ up to 48 hours post-dose] | 
| Elimination terminal half-life (t1/2) of SSS17 | Plasma samples will be collected and the t1/2 will be assessed. | [up to 48 hours post-dose] | 
| Total amount of SSS17 excreted in urine over 24 hours (Ae0-24) | Urine sample will be collected at pre-specified intervals and Ae0-24 will be assessed. | only for one cohort (up to 72 hours post-dose) | 
| Fraction of SSS17 excretion during each collection interval (Fe0-24) | Urine sample will be collected at pre-specified intervals and Fe0-24 will be assessed. | only for one cohort (up to 72 hours post-dose) | 
| Total amount of SSS17 excreted in urine over 72 hours (Ae0-72) | Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed. | only for one cohort (up to 72 hours post-dose) | 
| Fraction of SSS17 excretion during each collection interval (Fe0-72) | Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed. | only for one cohort (up to 72 hours post-dose) | 
| Renal clearance (CLR) of SSS17 | Urine sample will be collected at pre-specified intervals and CLR will be assessed. | only for one cohort (up to 72 hours post-dose) | 
| EPO concentrations | Change of EPO concentrations from baseline following SSS17 | up to 168 hours post-dose. | 
| VEGF concentrations | Change of VEGF concentrations from baseline following SSS17 | up to 168 hours post-dose. | 
| Change of RTC from baseline | Change of RTC from baseline following SSS17 | up to 168 hours post-dose. | 
| Change of RBC from baseline | Change of RBC from baseline following SSS17 | up to 168 hours post-dose. | 
| Change of Hgb from baseline | Change of Hgb from baseline following SSS17 | up to 168 hours post-dose. | 
| Change of hepcidin from baseline | Change of serum hepcidin concentrations from baseline following SSS17 | up to 168 hours post-dose. |